[en] Objective: To evaluate the preferences of patients with osteoarthritis for treatment.
Methods: A discrete-choice experiment was conducted among adult OA patients who were presented with 12 choice sets of two treatment options and asked in each to select the treatment they would prefer. Based on literature reviews, expert consultation, patient survey and expert meeting, treatment options were characterized by seven attributes: improvement in pain, improvement in walking, ability to manage domestic activities, ability to manage social activities, improvement in overall energy and well-being, risk of moderate/severe side effects and impact on disease progression. Random parameters logit model was used to estimate
patients’ preferences and a latent class model was conducted to explore preferences classes.
Results: 253 OA patients from seven European countries were included (74% women; mean age 71.3 years). For all seven treatment attributes, significant differences were observed between levels. Given the range of levels of each attribute, the most important treatment attribute in this group was impact on disease progression (29.5%) followed by walking improvement (17.1%) and pain improvement (16.3%). The latent class model identified two preference classes. In the first class (probability of 56%), patients valued impact of disease
progression the most (39%). In the second class, walking improvement and improvement in overall energy and well-being were the most important (23%).
Conclusion: This study suggests that all seven treatment attributes were important for OA patients. Overall, given the range of levels, the most important outcomes were impact on disease progression and improvement in pain and walking.
Disciplines :
General & internal medicine Public health, health care sciences & services
Author, co-author :
Hiligsmann, M.
Dennison, E.
Beaudart, Charlotte ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Herrero-Beaumont, G.
Branco, J.
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Conaghan, P.G.
Cooper, C.
Al-Daghri, N.
Jiwa, F.
Lems, W.
Pinto, D.
Rizzoli, R.
Thomas, T.
Uebelhart, D.
Veronese, N.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
de Wit, M., Cooper, C., Tugwell, P., Bere, N., Kirwan, J., Conaghan, P.G., Roberts, C., Aujoulat, I., Al-Daghri, N., Araujo de Carvalho, I., et al. Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res 31:7 (2019), 905–915.
Hunter, A., Facey, K., Thomas, V., Haerry, D., Warner, K., Klingmann, I., May, M., See, W., EUPATI guidance for patient involvement in medicines research and development: health technology assessment. Front Med (Lausanne), 5, 2018, 231.
Bridges, J.F., Hauber, A.B., Marshall, D., Lloyd, A., Prosser, L.A., Regier, D.A., Johnson, F.R., Mauskopf, J., Conjoint analysis applications in health–a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 14:4 (2011), 403–413.
Hiligsmann, M., Pinto, D., Dennison, E., Al-Daghri, N., Beaudart, C., Branco, J., Bruyere, O., Conaghan, P.G., Cooper, C., Herrero-Beaumont, G., et al. Patients' preferences for osteoarthritis treatment: the value of stated-preference studies. Aging Clin Exp Res 31:1 (2019), 1–3.
Clark, M.D., Determann, D., Petrou, S., Moro, D., de Bekker-Grob, E.W., Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics 32:9 (2014), 883–902.
Soekhai, V., de Bekker-Grob, E.W., Ellis, A.R., Vass, C.M., Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics 37:2 (2019), 201–226.
Hazlewood, G.S., Bombardier, C., Tomlinson, G., Thorne, C., Bykerk, V.P., Thompson, A., Tin, D., Marshall, D.A., Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment. Rheumatology (Oxford) 55:11 (2016), 1959–1968.
Kanis, J.A., Burlet, N., Cooper, C., Delmas, P.D., Reginster, J.Y., Borgstrom, F., Rizzoli, R., European society for C, economic aspects of O, osteoarthritis: European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:4 (2008), 399–428.
Bruyere, O., Cooper, C., Pelletier, J.P., Maheu, E., Rannou, F., Branco, J., Luisa Brandi, M., Kanis, J.A., Altman, R.D., Hochberg, M.C., et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-from evidence-based medicine to the real-life setting. Semin Arthritis Rheum 45:4 Suppl (2016), S3–11.
Cross, M., Smith, E., Hoy, D., Nolte, S., Ackerman, I., Fransen, M., Bridgett, L., Williams, S., Guillemin, F., Hill, C.L., et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73:7 (2014), 1323–1330.
Fraenkel, L., Suter, L., Cunningham, C.E., Hawker, G., Understanding preferences for disease-modifying drugs in osteoarthritis. Arthritis Care Res (Hoboken) 66:8 (2014), 1186–1192.
Berchi, C., Degieux, P., Halhol, H., Danel, B., Bennani, M., Philippe, C., Impact of falling reimbursement rates on physician preferences regarding drug therapy for osteoarthritis using a discrete choice experiment. Int J Pharm Pract 24:2 (2016), 114–122.
Byun, J.H., Kwon, S.H., Lee, J.E., Cheon, J.E., Jang, E.J., Lee, E.K., Comparison of benefit-risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments. Patient Prefer Adher 10 (2016), 641–650.
Arden, N.K., Hauber, A.B., Mohamed, A.F., Johnson, F.R., Peloso, P.M., Watson, D.J., Mavros, P., Gammaitoni, A., Sen, S.S., Taylor, S.D., How do physicians weigh benefits and risks associated with treatments in patients with osteoarthritis in the United Kingdom?. J Rheumatol 39:5 (2012), 1056–1063.
Laba, T.-L., Brien, J.-A., Fransen, M., Jan, S., Patient preferences for adherence to treatment for osteoarthritis: the MEdication Decisions in Osteoarthritis Study (MEDOS). BMC Musculoskelet Disord, 14, 2013, 160.
Ratcliffe, J., Buxton, M., McGarry, T., Sheldon, R., Chancellor, J., Patients' preferences for characteristics associated with treatments for osteoarthritis. Rheumatology (Oxford) 43:3 (2004), 337–345.
Hauber, A.B., Gonzalez, J.M., Groothuis-Oudshoorn, C.G.M., Prior, T., Marshall, D.A., Cunningham, C., Ijzerman, M.J., Bridges, J.F.P., Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value in Health 19:4 (2016), 300–315.
Janssen, E.M., Marshall, D.A., Hauber, A.B., Bridges, J.F.P., Improving the quality of discrete-choice experiments in health: how can we assess validity and reliability?. Expert Rev Pharm Out 17:6 (2017), 531–542.
de Bekker-Grob, E.W., Donkers, B., Jonker, M.F., Stolk, E.A., Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient 8:5 (2015), 373–384.
Zhou, M., Thayer, W.M., Bridges, J.F.P., Using latent class analysis to model preference heterogeneity in health: a systematic review. Pharmacoeconomics 36:2 (2018), 175–187.
Hauber, A.B., Arden, N.K., Mohamed, A.F., Johnson, F.R., Peloso, P.M., Watson, D.J., Mavros, P., Gammaitoni, A., Sen, S.S., Taylor, S.D., A discrete-choice experiment of United Kingdom patients' willingness to risk adverse events for improved function and pain control in osteoarthritis. Osteoarthr Cartil 21:2 (2013), 289–297.
Karsdal, M.A., Michaelis, M., Ladel, C., Siebuhr, A.S., Bihlet, A.R., Andersen, J.R., Guehring, H., Christiansen, C., Bay-Jensen, A.C., Kraus, V.B., Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future. Osteoarthr Cartil 24:12 (2016), 2013–2021.
Bansback, N., Trenaman, L., Harrison, M., How important is mode of administration in treatments for rheumatic diseases and related conditions?. Curr Rheumatol Rep, 17(Jun (6), 2015, 514.
